Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCV Positive Donor Hearts in HCV Negative Recipients
NCT03222531Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Jun 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of velpatasvir in hepatitis C (HCV) (2 arms). Primary endpoints: Adverse Events at 5 years and HCV free at 1 year. Started Aug 2017; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03222531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222531.